ProCAncer-I Project Dissemination Event in Vienna

An AI Platform integrating imaging data and models, supporting precision care through prostate cancer’s continuum: In Europe, prostate cancer (PC) is the second most frequent type of cancer in men and the third most lethal. Current clinical practices lead to overdiagnosis and overtreatment, necessitating more effective tools for discriminating between aggressive and non-aggressive disease. The EU-funded ProCAncer-I project proposes to develop advanced artificial intelligence models to address unmet clinical needs: diagnosis, metastases detection and prediction of response to treatment. To achieve this, partners will generate a large interoperable repository of health images, and a scalable high-performance computing platform hosting the largest collection of PC Magnetic Resonance Images used for developing robust PC AI models. To ensure the rapid clinical implementation of the models developed, the project’s partners will robustly monitor performance, accuracy and reproducibility. 

Welcome by Coordinating Team

We are very glad to lead a very ambitious and health-driven project that could end to alleviating and helping thousands of men to tackle prostate cancer in a more personalized way supporting a better quality of life

The Coordinating Team

Manolis Tsiknakis

Prof. Manolis Tsiknakis
(Coordinator)

Dr. Nikolaos Papanikolaou
(Scientific Manager)

Prof. Kostas Marias
(Technical Manager)

Prof. Daniele Regge
(Clinical Manager)

The ProCAncer-I project is one of the founding projects of the FUTURE-AI.

FUTURE-AI is an international, multi-stakeholder initiative for defining and maintaining concrete guidelines that will facilitate the design, development, validation, and deployment of trustworthy AI solutions in medical imaging based on six guiding principles: Fairness, Universality, Traceability, Usability, Robustness, and Explainability.

Project Information

Months (Duration)

Euros (Total Budget )

Grant Agreement Nr.

Funded

This project has received funding from the European Union’s Horizon 2020 research and innovation programme

|

Topic

DT-TDS-05-2020:
AI for Health Imaging

Highlights

The brand effect: how different MRI machines trip up AI

The brand effect: how different MRI machines trip up AI

Prostate cancer can vary greatly in how aggressive it is, and knowing this in advance helps doctors decide the best course of treatment. Magnetic resonance imaging (MRI) is often used to detect prostate cancer, but figuring out just how aggressive the cancer is...

Dissemination Event of the ProCAncer-I Project in Vienna

Dissemination Event of the ProCAncer-I Project in Vienna

We are delighted to invite you to our session, “ProCAncer-I: An AI Platform Integrating Multiparametric MRI and AI Models”, at the European Congress of Radiology (ECR) 2025.  Date: 26 February 2025  Time: 15:00 – 16:00  Location: ECR 2025, Vienna, Austria (conference...

ProCAncer-I at the ECR 2025 in Vienna

ProCAncer-I at the ECR 2025 in Vienna

ProCAncer-I will organise a Dedicated Session on the project during the European Congress of Radiology 2025 on the 26th of February 2025, at 15.00-16.00, with the title "ProCAncer-I: an AI platform integrating multiparametric MRI and AI models" where we will present...

Twitter feed is not available at the moment.

Stay in touch!